D. E. Shaw & Co., Inc. Avidity Biosciences, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $114 Billion
- Q1 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 31,266 shares of RNA stock, worth $1.21 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
31,266
Previous 41,486
24.63%
Holding current value
$1.21 Million
Previous $375,000
112.53%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding RNA
# of Institutions
164Shares Held
71.6MCall Options Held
182KPut Options Held
55K-
Rtw Investments, LP New York, NY7.97MShares$309 Million3.26% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD7.43MShares$288 Million0.02% of portfolio
-
Black Rock Inc. New York, NY6.17MShares$239 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.83MShares$226 Million1.79% of portfolio
-
Cowen And Company, LLC5.63MShares$218 Million4.83% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $2.02B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...